Joe Tippens (publishing other patients' stories), 2018-06: Tippens's June 2018 post collects six or more second-hand patient stories – pancreatic, prostate, colorectal, non-small cell lung and small-cell lung cancer – that he says shrank or disappeared on his fenbendazole regimen.
Over the last 11 months, approximately 25 people with varying kinds and stages of cancer have started the regimen outlined here on this blog.
Post body (unpaginated)
Joe Tippens (publishing other patients' stories), 2018-06: Tippens's June 2018 post collects six or more second-hand patient stories – pancreatic, prostate, colorectal, non-small cell lung and small-cell lung cancer – that he says shrank or disappeared on his fenbendazole regimen. Patient-reported, not independently verified. These are testimonials relayed by Tippens, not case reports with records; no patient is named, no pathology or scan report is reproduced, and the outcomes rest on the patients' own reports to him. Reported details as published: about 25 people started the regimen in 11 months; examples include two stage IV pancreatic cancers 'given 3 months to live' whose tumours 'shrunk almost to non-existence', a widely metastatic prostate cancer whose 'tumors have all shrunk considerably', and a metastatic colorectal cancer patient who stopped her oral chemo without telling anyone. Doses are not given in this post (they point to the blog's protocol page: 1 g Panacur C, about 222 mg fenbendazole, 3 days on/4 off). No funder or conflict statement. Study type: other.
